Neel Gakhar
Hospitalist · Denver, CONPI 1073977153
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,397 of the $2,770 with a category attached, or 86.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $25.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$472
- Incyte Corporation$356
- Lilly USA, LLC$353
- Daiichi Sankyo Inc.$258
- AstraZeneca$218
- Novartis$172
- plus $943 from 16 others
What the payments were for
- Food & beverage$2,39787%
- Education$37313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $472 |
| Incyte Corporation | 7 | $356 |
| Lilly USA, LLC | 10 | $353 |
| Daiichi Sankyo Inc. | 11 | $258 |
| AstraZeneca(2 entities) | 9 | $218 |
| Novartis | 8 | $172 |
| Merck | 7 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $108 |
| Regeneron Healthcare Solutions, Inc. | 4 | $105 |
| Seagen Inc. | 2 | $93 |
| Eisai Inc. | 4 | $85 |
| GSK | 4 | $82 |
| Mirati Therapeutics, Inc. | 3 | $69 |
| Sanofi | 2 | $53 |
| Genentech USA, Inc. | 2 | $38 |
| Bristol Myers Squibb | 1 | $33 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Myriad Genetic Laboratories, Inc. | 1 | $23 |
| Pharmaand GmbH | 4 | $20 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$125
How this compares
$2,770 in reported general payments places this provider in the 95th percentile of 547 hospitalist providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 13 | $187,767 |
| KeytrudaPembrolizumab | 13 | $145,549 |
| XgevaDenosumab | 13 | $44,232 |
| Lupron DepotLeuprolide Acetate | 11 | $26,173 |
| Bortezomib | 11 | $1,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckKeytruda | $155 | $145,54913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 547 hospitalist providers in Colorado.
Other hospitalist in Denver
- John HornsbyDenver$1K
- Kimberly Schatz MartinDenver$1K
- Joseph RamharackDenver$535
- Spencer PetersonDenver$521
- Jennifer GrayDenver$470
- Daniel LevyDenver$402
- Ryan FriedmanDenver$355
- Tejas PatilAurora$94K
- Janna Gelderman-MoffettLouisville$34K
- Michael SolaAurora$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.